Sensitization of colonic nociceptors by TNFα is dependent on TNFR1 expression and p38 MAPK activity.
Higham, James P
Pattison, Luke A
Taylor, Toni S
Chessell, Iain P
Smith, Ewan St J
MetadataShow full item record
Barker, K. H., Higham, J. P., Pattison, L. A., Taylor, T. S., Chessell, I. P., Welsh, F., Smith, E. S. J., & et al. (2022). Sensitization of colonic nociceptors by TNFα is dependent on TNFR1 expression and p38 MAPK activity.. J Physiol https://doi.org/10.1113/JP283170
Visceral pain is a leading cause of morbidity in gastrointestinal diseases, which is exacerbated by the gut-related side-effects of many analgesics. New treatments are needed and further understanding of the mediators and mechanisms underpinning visceral nociception in disease states is required to facilitate this. The pro-inflammatory cytokine TNFα is linked to pain in both patients with inflammatory bowel disease and irritable bowel syndrome, and has been shown to sensitize colonic sensory neurons. Somatic, TNFα-triggered thermal and mechanical hypersensitivity is mediated by TRPV1 signalling and p38 MAPK activity respectively, downstream of TNFR1 receptor activation. We therefore hypothesized that TNFR1-evoked p38 MAPK activity may also be responsible for TNFα sensitization of colonic afferent responses to the TRPV1 agonist capsaicin, and noxious distension of the bowel. Using Ca2+ imaging of dorsal root ganglion sensory neurons, we observed TNFα-mediated increases in intracellular [Ca2+ ] and sensitization of capsaicin responses. The sensitizing effects of TNFα were dependent on TNFR1 expression and attenuated by p38 MAPK inhibition. Consistent with these findings, ex vivo colonic afferent fibre recordings demonstrated an enhanced response to noxious ramp distention of the bowel and bath application of capsaicin following TNFα pre-treatment. Responses were reversed by p38 MAPK inhibition and absent in tissue from TNFR1 knockout mice. Our findings demonstrate a contribution of TNFR1, p38 MAPK and TRPV1 to TNFα-induced sensitization of colonic afferents, highlighting the potential utility of these drug targets for the treatment of visceral pain in gastrointestinal disease. KEY POINTS: The pro-inflammatory cytokine TNFα is elevated in gastrointestinal disease and sensitizes colonic afferents via modulation of TRPA1 and NaV 1.8 activity. We further develop this understanding by demonstrating a role for p38 MAPK and TRPV1 in TNFα-mediated colonic afferent sensitization. Specifically, we show that: TNFα sensitizes sensory neurons and colonic afferents to the TRPV1 agonist capsaicin. TNFα-mediated sensitization of sensory neurons and colonic nociceptors is dependent on TNFR1 expression. TNFα sensitization of sensory neurons and colonic afferents to capsaicin and noxious ramp distension is abolished by inhibition of p38 MAPK. Collectively these data support the utility of targeting TNFα, TNFR1 and their downstream signalling via p38 MAPK for the treatment of visceral pain in gastrointestinal disease.
TRPV1, capsaicin, inflammatory bowel disease, irritable bowel syndrome, nociception, p38 MAPK, tumour necrosis factor-alpha, visceral pain, Animals, Capsaicin, Ganglia, Spinal, Mice, Nociceptors, Receptors, Tumor Necrosis Factor, Type I, TRPV Cation Channels, Tumor Necrosis Factor-alpha, Visceral Pain, p38 Mitogen-Activated Protein Kinases
Is supplemented by: https://doi.org/10.17863/CAM.81112
Biotechnology and Biological Sciences Research Council (BB/M011194/1)
External DOI: https://doi.org/10.1113/JP283170
This record's URL: https://www.repository.cam.ac.uk/handle/1810/339392
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: firstname.lastname@example.org